Endothelial cells (EC) may represent a major source of cytokines in the bone marrow. In this study we have examined the production and the regulation of the production of leukemia inhibitory factor/human interleukin for DA cells (LIFI HILDA) by EC. Human umbilical vein endothelial cells (HU-VEC) were chosen as a working model as they are a well known source of cytokines. These cells secrete LIF/HILDA (90 pg/mL/10' cells/48 h) in basal conditions. This secretion is profoundly altered by interleukin-la (IL-la). Secretion of LIF/HILDA is increased threefold on stimulation with IL-la at a concentration of 100 IU/mL. The secreted protein is bioactive as demonstrated by its proliferative effects on DAla cells. Modulation of the production of LIF/HILDA by glucocorticoids (GC) was also examined. In striking contrast to what was observed for IL-la, the synthetic GC dexamethasone (DXM) at a concentration of lo-' mol/L consistently inhibited the basal secretion of LIF/HILDA by an average of HE SELF-RENEWAL, proliferation, and differentiation of multipotent stem cells and committed progenitor cells involves a number of cytokines that act in a complex and largely unknown way. The complexity of the regulation of the proliferative, differentiative, and maturation events of hematopoiesis depends for a good part on the number and the high degree of redundancy of these molecules. Most of the cytokines regulating hematopoiesis are being produced locally by the various cell types constituting the bone marrow stromal microenvironment. Most of the mRNA transcripts for these cytokines have been found in stromal cells and the secretion of bioactive molecules has been demonstrated for some of them such as granulocyte macrophage (GM) and granulocyte (G) colony-stimulating factor (CSF), stem cell factor (SCF), and interleukin-6 (IL-6).I4 In most cases these studies have been using long-term cultures of human bone marrow stromal cells made of a number of different cells, such as macrophages, fibroblasts, adipocytes, and endothelial cells (EC). These studies therefore did not discriminate between these cells to delineate which one(s) is (are) the source of cytokine production. In order to dissect the complex regulatory network of these cytokines in hematopoiesis, it is important to understand which cytokine is produced and secreted by which cell, how their production is regulated, and how each of the cytokine-producing cells are interacting with regards to the hematopoietic cells.
We have initiated an analysis of the production and the regulation of the production of leukemia inhibitory factor/ human interleukin for DA cells (LIFIHILDA) by bone marrow stromal cells. LIFHLDA is a pleiotropic cytokine formerly identified in the supernatants of T-cell clones by its ability to support the proliferation of the murine IL-3-dependent DAla cell line.5 T h i s molecule turned out to be identical to the LW."' LIFIHILDA has a wide range of target cells. For instance, LIF/HILDA induces proliferation and suppresses spontaneous differentiation of embryonic stem cells, induces production of several acute phase proteins by hepatocytes,"
Blood, Vol86, No 10 (November 15), 1995: pp 3763-3770 T threefold and suppressed the IL-la-induced increase of the secretion of this cytokine by HUVEC. In an effort to extend results obtained with HUVEC to the bone marrow endothelium, we have also examined the production of LlFlHlLDA by human bone marrow endothelial cells (HBMEC). Our study shows that HBMEC are quantitatively a very important source of this cytokine (above 7.25 ng/mL/10' cells/48 h) suggesting that they are a major source of LlFlHlLDA in the bone marrow. Again, IL-la proved to be a very potent stimulus for the secretion of LIF/HILDA and synthetic GC such as DXM when used at a concentration of lo-' mol/L inhibited by an average of threefold the basal secretion of LIF/HILDA and had a suppressive effect on the IL-la-induced increase of this secretion. The downregulation of LIF/HILDA production in the bone marrow by GC may be important to understand the effects of GC on hematopoiesis. 0 1995 by The American Society of Hematology.
and is a differentiation factor for cholinergic neurons." In addition LIFIHILDA is probably a good candidate as a regulatory molecule for differentiation and proliferation of hematopoietic progenitor cells. However, its effect on these cells is far from clear. Apart from its known differentiation promoting effects on a murine leukemia cell line, M1, LIF/ HILDA stimulates platelet formation,'* stimulates myeloid and erythroid colony formation of human mononuclear phagocyte and T-lymphocyte-depleted bone and is a synergistic factor for the IL-3-dependent proliferation of early hematopoietic progenitor cells in a blast cell colony assay.I4 But conflicting data also exist15 and the precise role of LIF, whether it acts directly or indirectly by inducing the release by stromal cells of other mediators or acts only in synergy, remains to be determined.
In the current study, we have studied the production of 
MATERIALS AND METHODS

EC From Umbilical Cord
Primary cultures of HUVEC were obtained from freshly collected umbilical cords. 0.1% wt/vol collagenase (Boehringer Mannheim, Meylan, France) was used for treatment of the umbilical vein instead of 0.2%, as originally described.I6 HUVEC were cultured in Iscove's modified Dulbecco's medium (IMDM; GIBCO, Cergy-Pontoise, France) supplemented with 20% heat-inactivated fetal calf serum (FCS), 15 pg/mL EC growth factor supplement (ECGS, E0760; Sigma, Saint-Quentin, France), 90 pg/mL heparin (Sigma), penicillin (100 IU/mL), streptomycin (50 pg/mL), and amphotericin B (2.5 pg/mL). This culture medium is referred to as standard medium. Cells were grown to confluence in 75 or 25 cmz flasks coated with 100 pg/mL collagen I (Jacques Boy Institute, Paris, France). Cells were passaged after treatment with trypsin-EDTA and routinely used between the second and fourth passages. After the second passage, there was no visible contamination by monocytes. Cells were maintained in a humidified atmosphere at 37°C 5% COz, and were identified by their characteristic morphology and by the expression of factor VI11 antigen.
EC From Bone Marrow Microvasculature
EC from human bone marrow (BM) microvasculature were isolated following a two-step procedure with BNH-9 coated microspheres. BNH-9 is a mouse IgM monoclonal antibody recognizing EC specific H and Y antigens (Immunotech, Marseille, France). The whole procedure is essentially the same as that described by Rafii et all' with slight modifications.
Briefly, normal fresh BM samples were collected from the femoral head or posterior iliac crest from patients undergoing orthopedic surgery or from individuals donating BM for allogenic BM transplantation. Informed consent was obtained from each donor. The BM sample (5 to 30 mL total) was diluted 1:l in buffer A (RPMI containing 5 mmol/L EDTA), placed on a 40 pm Cell Strainer Falcon disposable filter, and washed five times with buffer A while being gently triturated. Mononuclear cells (MNC) were separated from filtrate by standard Ficoll-hypaque centrifugation (Sigma; specific gravity, 1.077) at 800s for 20 minutes at 24T, and kept for further isolation as they also contain HBMEC. To avoid binding of the BM fat ladder spicules to the surfaces, plasticwares at this step were treated with 1% bovine serum albumin (BSA) in RPMI. The filter was cut out, placed in a 50 mL Falcon tube and digested in 10 mL of 0.1% collagenase for 15 minutes at 37°C. The digested material was gently passaged several times through a 1 mL tip to obtain the microvessels fragments. This material was washed twice with buffer B (RPMI containing 2% FCS) and then gently triturated to further dissociate the EC.
HBMEC were further isolated by positive selection using BNH-9-coated tosyl-activated Dynabeads (BNH-9 diluted 1:20) (Dynal SA, France). Isolation using BNH-9-coated microspheres was essentially performed as described by Schweitzer et al.'* Coating of the beads was performed following manufacturer's instructions. '9 Briefly, cells from digested material and MNC from filtrate were incubated for 30 minutes at +4"C at a density of 1. lo6 cells/mL with BNH-9-coated beads at a bead ratio of 50 beads per EC (estimated at 1% of total isolated cells). Then, the cell-bead aggregates were washed seven times by mixing cells for 1 minute at room temperature on a rotator with 5 mL of buffer B; aggregates were separated from unbound cell supernatant with a magnetic particle concentrator (MPC). After the final wash, EC were collected, washed once with complete medium, and plated in collagen-coated dishes or flasks as above, on collagen I-coated 6-wells Nunc Plastic dishes in IMDM containing 20% FCS, 15 pg/mL ECGF, 90 pg/mL heparin, antibiotics, and fungizone.
HBMEC were characterized by their expression of von Willebrand Factor (vWF) by immunofluorescence and flow cytometry with Epics-Profile I1 cytometer (Coulter), and the presence of WeibelPalade bodies by electronic microscopy examination (Philips microscope).
Cytokine Preparations and Other Reagents
IL-1 was human rIL-la purified from Escherichia coli, a gift from Dr PT Lomedico, Hoffman-La Roche, Inc. Nutley, NJ; dexamethasone (DXM) sodium phosphate salt (sterile, apyrogenic solution for human therapeutic use) was purchased from Merck, Sharp, and Dohme, Chibret, Paris, France; hydrocortisone (HC) was purchased from Sigma.
LIF/HLDA Proteins and Antisera
Monoclonal antibodies IF10 and 7D2 (IgGl mouse monoclonal antibodies) were obtained as previously described.*' Briefly, mice were immunized with recombinant vaccinia virus harboring the cDNA pC10-6R7 encoding the complete sequence for human LIF/ HILDA. The resulting monoclonal antibodies were screened by a cytofluorometric assay, in which the LIFHLDA antigen, as a fusion molecule, was expressed at the membrane of a stably transfected P815 cell line.
Purified LIF is recombinant human protein obtained from CH0 cells stably transfected with pC10-6R encoding the complete coding sequence for human LIFEIILDA. Transfected cells produce LIF in the range of 1 to 2 pg/mL in their supematants.
Experimental Procedures
HUVEC and HBMEC cultures. Confluent HUVEC or HBMEC monolayers were incubated in medium containing the indicated stimuli. Working concentrations were 100 IU/mL for E -l a , moU L for HC, and mol/L for DXM. Cells were stimulated for the indicated time, the supernatants were collected, centrifuged for 10 minutes at 4°C decanted in a fresh tube, added with Tween 20 0.05% final, and kept at 4°C until they were assayed for LIFMEDA (addition of Tween prevents denaturation of the LIFMILDA protein, whereas freezing and thawing the sample tends to give loss of bioactive protein [unpublished observations, June 19931).
CD34'/38'"" isolation. In some experiments, CD34'/CD38'"" hematopoietic progenitors were cocultivated with a HUVEC or a HBMEC monolayer in stroma "non-contact'' system with Transwell inserts essentially as described." CD34' cells were isolated from cord blood. MNC were separated by standard Ficoll-hypaque centrifugation as described before. Hematopoietic progenitors expressing the CD34 antigen were purified using the Isolex 50 system (Baxter, Maurepas, France) following the manufacturer's instructions. TO isolate immature CD34+/CD38'"" cells, a two-color staining of immunomagnetically isolated CD34' cells was performed with anti-CD34 fluorescein isothiocyanate (FITC) monoclonal antibody (HPCA-2, Beckton Dickinson, San Jose, CA), anti-CD38 phycoerythrin (PE) and anti-Leu-7 monoclonal antibody (Beckton Dickinson). Cells were then incubated for 30 minutes at +4"C and washed twice. Negative controls were cells labeled with appropriate isotypic controls (mouse IgG,-PE and mouse IgG,-FITC). Cells were sorted
a FACS (PC 3000, Odam-Bmcker, Wissenbourg, France). Selection consisted of (1) gating in side-scattedforward-scatter bivariate distributions by suppression of background and cell aggregates, and (2) recovering CD34'CD38'"" cells on a CD34-FITC/CD38-PE bivariate histogram against negative control antibodies.
Coculrures. CD34' or CD34'/CD38'"" cells were cocultivated in the presence of HUVEC monolayers in IMDM, 20% FCS, and antibiotics. Two of five of the medium were replaced twice a week. After 7, 14, or 21 days, the culture medium was collected, centrifuged for 10 minutes at 8008, decanted to a fresh tube, added with Tween 20 0.05% final, and kept at +4"C until being assayed for LIFMILDA. Controls were HUVEC cultivated under the same conditions in the absence of CD34'/CD38'"" progenitors. Where indicated, IL-la was added.
EIA and DAla Bioassays
The first antibody IF10, diluted at IO pg/mL in carbonate buffer, was coated overnight on 96-well microplates (Maxisorp Nunc, Denmark). After washing with PBS-Tween 20 0.005% (PBS-T), cell supernatants (0.1 mL) were incubated for 90 minutes and further washed with PBS-T. The second biotinylated antibody (7 D2) was diluted in PBS-BSA 0.1% at 1 pg/mL and allowed to react for 90 minutes before washing with PBS-T. The reaction was amplified by peroxydase-linked streptavidin (Amersham, Little Chalfont, UK) and revealed with tetramethyl benzidin (Sigma, France). All incubations were conducted at room temperature. The variations of optical densities were measured with an EIA reader at 450 and 570 nm (Labsystem Multiskan), with a mean of 6 HILDALIF negative controls being subtracted for each point. The threshold of detection was determined as the mean of these 6 control measurements plus 2 standard errors, and never exceeded 25 pg/mL in culture supernatants.
The DAI a proliferative assay, has already been described, and is based on the LIF-induced proliferation of the murine DAla cell line.' In this assay, one unit is the quantity of LIF able to provide 50% of the maximal DAla proliferation. In a previous study, it was found to be equal to 25 pg.' Both assays were concordant.
Northern Blot Analysis
Total cellular RNA was extracted from HUVEC monolayers as described.22 RNA was denatured using fonnamide and formaldehyde and electrophoresis was performed on gels containing formaldehyde. Double-stranded cDNA probes were the human LIF cDNA excised as a 0.6 kb Xhol/XhoI insert from the plasmid pC10-6R7 and an actin cDNA probe (chicken cytoskeleton actin) from ATCC. Probes were labeled with "P by random priming (Boehringer Mannheim). RNA loading was checked by ethidium bromide staining and control hybridization of the blot with the actin probe.
Statistical Methods
Significant differences between values obtained in each assay were determined by paired Student's t-test. The difference was considered significant when P < .05.
RESULTS
LIF/HILDA Production by HUVEC: Differential Regulation by IL-la and GC
Biosynthesis of LIFMILDA was investigated by EIA in the supernatants of HUVEC grown in IMDM, 20% FCS, and antibiotics. The HUVEC were grown at confluence and 3765 stimulated with either IL-la and/or DXM for 48 hours. ECGF was omitted to avoid any possible contamination by a protein that would have interfered with the assay. We chose IL-la as it has been shown to be a potent inducer of cytokine secretion by EC. The effects of DXM were also investigated to study the potential downregulation of EC-derived cytokines by this synthetic glucocorticoid. Results summarized in Fig 1, show that H W E C spontaneously secreted LIF/ HILDA in their supernatants. The median level of five experiments for basal secretion was 90 pg/mL/106 cells/48 h. Production of LIFMILDA was significantly increased by threefold ( P = .01) when HUVEC were being stimulated by IL-1 a at a final concentration of 100 IU/mL. Other concentrations were not investigated. We next studied the potential regulatory activity of synthetic glucocorticoids on the production of LIFMILDA. We found that DXM at a final concentration of mom consistently inhibited the basal production of LIF/HILDA by an average of threefold ( P = .005). Furthermore, there was a striking suppressing effect of DXM on the IL-la-induced increase in LIF/HILDA production (P = .005). In the presence of both DXM ( mol/ L) and IL-la (100 IU/mL), the production of LIF/HILDA is close to control levels (P = .20) (Fig 1) . 
LIFMILDA Is Produced by HBMEC: Quantitative Importance of This Secretion and Modulation by IL-la and GC
In an effort to understand whether EC from the bone marrow microvasculature also produce LIFMILDA and to study the regulation of this production, we isolated HBMEC from normal bone marrow. These cells are thought to play an important role in the local production of cytokines necessary for hematopoiesis. Secretion of LIFMILDA in the supernatants of these cells was analyzed in basal conditions and after 48 hours of stimulation by IL-la (100 IU/mL). Results indicated that HBMEC are a quantitatively important source of LIFMILDA (median level was 7.25 ng/mL/1O6 cells/48 h, n = 4) (Fig 2) . These results show that basal production of LIFMILDA is quantitatively strikingly more important in HBMEC than in HUVEC (approximately 80-fold). Again, IL-la profoundly increased the production of this cytokine. In the presence of IL-la, the secretion of LIFMILDA by HBMEC was significantly increased by an average of threefold ( P = .03). Again, as observed with HUVEC, DXM at a final concentration of moIL inhibited by threefold the basal secretion of LIFMILDA ( P = .01)
GROSSET ET AL and suppressed the IL-la-induced increase of LIFMILDA secretion (Fig 2) . HC at mom gave the same results
(not shown).
IL-la Enhancement of LIFMILDA Messenger RNA
The level of LIFMILDA mRNA and regulation of its expression by IL-la was examined by Northern hybridization on HUVEC grown and stimulated in standard growth medium. The blot was first hybridized with LIFMILDA cDNA probe and was subsequently re-hybridized with a chicken actin cDNA probe as an internal control. Results (Fig 3) show that the level of LIF message is difficult to detect in basal conditions and that IL-la induces a strong increase in the expression of this message. These results suggest that the IL-la modulation of LIFMILDA expression in EC occurs primarily at the mRNA level.
LIFMILDA Secreted by EC is Biologically Active
Bioactivity of LIFMILDA secreted by HUVEC was measured by a DAla proliferative assay based on the LIF/ HILDA-induced proliferation of the murine DAla cell line. Fifty microliters of culture supernatants' dilutions were incubated for 72 hours at 37°C with 50 pL of 1.5 IO4 DAla cells. The LIFMILDA biologic activity in the supernatants of control HUVEC reached 36 DAla U124 h. This activity was increased to 80 U 2 4 h in the supernatants of IL-lastimulated cells. These results are in agreement with the EIA assay and suggest that no other cytokines besides LIF/ HILDA, which might interfere with the DAla cell proliferation assay, are being secreted by these cells (Fig 4) . 
DILUTIONS OF CULTURE SUPERNATANTS
Kinetic Analysis of LIFLHILBA Production in Cocultures of Hematopoietic Progenitor Cells With HUVEC
To analyze the production and regulation of the production of LIFMILDA in an experimental system that would reflect more closely the physiologic hematopoiesis, we set up experiments in which human hematopoietic progenitor cells were cocultivated with EC as a stromal layer. A non-contact system" with Transwell inserts was used. In this system cells are physically separated but soluble molecules allowing communication between stromal cells and the differentiating and proliferating hematopoietic cells diffuse freely within the two compartments. We asked the question whether LIF/ HILDA was being produced in such a system and how its concentration was varying during the coculture. As shown in Fig 5 , LIF/HILDA is being produced in increasing amounts over a period of 21 days in cocultures of HUVEC and CD34+. However, the kinetics of LIF/HILDA production in the cocultures is not significantly different to the control HUVEC (grown without CD34+ progenitors) whether IL-la is present or not. These results indicate that the differentiating and proliferating hematopoietic cells do not influence the production of LIFMILDA by the HUVEC stroma layer. Cocultures of HUVEC with CD34+/38loW progenitors gave identical results (not shown).
DISCUSSION
The local mechanisms by which the bone marrow microenvironment exerts its control over hematopoiesis still re-3161 mains to be clarified. One form of this control is based on the secretion of a wide array of growth factors in the immediate environment of the proliferating and maturing hematopoietic cells. The regulation of the expression of these growth factors is not understood. In vitro as well as in vivo data indicate that LIFMILDA probably has profound effects on proliferation and maturation of hematopoietic progenitor cells. In vitro, LIFMILDA was shown to support the growth of multipotential Cm-Mix colonies, with this effect being additive with other hematopoietic growth fa~t0rs.l~ More recently, Wetzler et alZ3 reported that neutralization of LIFMILDA reduces the number of CFU-GM progenitors. However there are conflicting in vitro data about the putative role of LIF/ HILDA in hematopoiesis. An absence of demonstrative proliferative effects of LIF/HILDA on mature progenitors has been reported.14.15.z4-26 In vivo data tend to accredit the working hypothesis that LIFMILDA plays an important function in hematopoiesis. There is an elevation of progenitor cells in the spleen of mice after injection of LIFMILDA, with a noticeable increase in megakaryocyte progenitors.'* The current idea is that the effects of LIFMILDA might be directed at a very primitive compartment as is suggested, for instance, by the increase in size of CFU-Mix and BFU-E colonies after bone marrow progenitor cultures in the presence of LIFMILDAl3 or by the LIFMILDA-induced augmentation of the IL-3-dependent proliferation of early human hematopoietic blast cell
In the present study we show that EC could represent a major source of bioactive LIF/HILDA in the bone marrow. The good correlation between the EIA and the DA l a biologic assay also suggests that oncostatine, which has a DAla proliferative activity, is not produced by HUVEC. In vitro, expression of LIF/HILDA by human bone marrow stromal cells has been demonstrated in recent studies. The LIF mRNA was detected in long-term bone marrow cultures and IL-1 or TNF-a also increased expression of this messenger; LIFMILDA protein was found in the supernatants of longterm bone marrow stroma culture." However the nature of the cells involved in this production remained to be determined. The bone marrow stroma is made of approximately 60% to 70% fibroblasts, 10% to 20% ECZ8 and other cells present in small amounts but with potential functional importance, such as adipocytes, macrophages, and osteoclasts. Fibroblasts may be one source of LIFMILDA in the bone marrow since its mRNA has been found in bone marrowderived stromal fibroblast cells.29 Our data support the idea that EC must be considered as significant LIFMILDA-producing cells in the bone marrow. EC have been shown to produce (almost nearly) all of the cytokines that are believed to play a role in the proliferation and maturation of the hematopoietic cells.30 More recently, SCF mRNA has been shown to be expressed3' and IL-11 protein to be produced by EC.32 These experiments further emphasize the fact that EC produce all the necessary factors to support hematopoiesis. In the current study we show that results obtained for LIF production by HUVEC can be extrapolated to HBMEC. The significantly higher production of LIF by HBMEC on a per cell basis might represent specialization of the EC of bone marrow toward the production of the cytokines neces-
